



Sheet 1 of 3

Form PTO-1449
(Reproduced)U. S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
PH-7218A CIPSERIAL NO.
10/786,935

INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

(Use several sheets if necessary)

APPLICANT
Robichaud et alFILING DATE
2/25/04GROUP
1624

U. S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
B.K.	AA	5 5 1 2 5 7 5	4/30/1996	Jacobs et al			
	AB	5 6 5 4 1 3 9	8/5/1997	Lappalainen et al			
	AC	5 9 0 2 8 1 5	5/11/1999	Olney et al			
	AD	5 9 0 8 8 3 0	6/1/1999	Smith et al			
	AE	6 1 0 7 3 2 4	8/22/2000	Behan et al			
	AF	6 1 4 0 5 0 9	10/31/2000	Behan et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AG						
	AH						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

B.K.	AI	Bickerdike MJ, Vickers, SP, Dourish CT, (1999) 5-HT _{2C} receptor modulation and the treatment of obesity. Diabetes, Obesity and Metabolism 1:207-214
	AJ	Tecott LH, et al. (1995) Eating disorder and epilepsy in mice lacking 5-HT _{2C} serotonin receptors. Nature (London) 374:542-546
	AK	Cryan JF, Lucki I, (2000) Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine _{2C} receptors. J. Pharmacol. Exper. Ther. 295:1120-1126
	AL	Millan MJ, Peglioni JL, Lavielle G, Perrin-Monneyron S, (1997) 5-HT _{2C} receptors mediate penile erection in rats: actions of novel and selective agonists and antagonists. Eur. J. Pharmacol. 325:9-12
	AM	Martin JR, et al. (1998) 5-HT _{2C} receptor agonists: Pharmacological characteristics and therapeutic potential. J. Pharmacol. Exper. Ther. 286:913-924
	AN	Meltzer HY. (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21(2):1065-1155

EXAMINER

Bruck K. J.

DATE CONSIDERED

8/12/04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449
(Reproduced)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
PH-7218 A CIPSERIAL NO.
10/786,935

INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

(Use several sheets if necessary)

APPLICANT
Robichaud et alFILING DATE
2/25/04GROUP
1624

U. S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA'						
	AB'						
	AC'						
	AD'						
	AE'						
	AF'						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES	NO
	AG'							
	AH'							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

D.K. ↓	AI'	Curzon et al, Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability, TIPS, Vol. 18, 1997; 21-25
	AJ'	Mora et al, Role of 5-HT2A and 5-HT2C Receptor subtypes in the Two Types of Fear Generated by the Elevated T-Maze, Pharma. Biolchem. & Behavior, Vol. 58, No. 4, 1997; 1051-1057
	AK'	Jenck et al, Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats, European Neuropsychopharmacology, 8, 1998; 161-168
	AL'	Leysen, Selective 5-HT2c agonists as potential antidepressants, Drugs, 1999, 2(2); 109-120
	AM'	Jenck et al, The role of 5-HT2c receptors in affective disorders, Exp. Opin. Invest. Drugs, 1998, 7(10); 1587-1599
	AN'	Kennett, 5-HT drugs and eating disorders, I Drugs, 1998, Vol. 1, No. 4; 456-470

EXAMINER

Brink Kiff

DATE CONSIDERED

8/12/04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449
(Reproduced)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
PH-7218A CIPSERIAL NO.
10/786,935

INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

(Use several sheets if necessary)

APPLICANT
Robichaud et alFILING DATE
2/25/04GROUP
1624

U. S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
D.K.	AA*	3 2 9 9 0 7 8	1/17/67	Pachter			
	AB*						
	AC*						
	AD*						
	AE*						
	AF*						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AG*						
	AH*						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

D.K.	AI*	Brewerton, Induction of migrainelike headaches by the serotonin agonist m-chlorophenylpiperazine, Clin. Pharmacol. Ther., 1988, 605-609
↓	AJ*	Kahn et al, m-Chlorophenylpiperazine as a probe of serotonin function, Biol. Psychiatry, 1991; 30: 1139-1166
↓	AK*	Gibson et al, Evidence that mCPP-induced Anxiety in the Plus-maze is mediated by Postsynaptic 5-HT _{2c} receptors but not by sympathomimetic effects, Neuropharmacology, Vol. 33, No. 3, 4, 1994; 457-465
	AL*	
	AM*	
	AN*	

EXAMINER

Druck K/A

DATE CONSIDERED

8/12/04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.